We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drug resistance in cancer.
- Authors
Yagüe, E.; Raguz, S.
- Abstract
Cancer Research UK has recently sponsored a meeting, organized by the UK Medical Research Council, on cancer drug resistance. Several of the molecular mechanisms responsible for this clinical outcome, such as DNA interstrand crosslink repair, apoptosis evasion, cytochrome P450 and P-glycoprotein, were discussed. There was a special focus on leukaemia, breast and ovarian cancer, and the potential use of positron-emission tomography to study anticancer-drug resistance. The progress made in translating these findings to the clinic, like Gefitinib, P-glycoprotein phenotyping, or genome-wide analysis technology, was also discussed.British Journal of Cancer (2005) 93, 973–976. doi:10.1038/sj.bjc.6602821 www.bjcancer.com Published online 18 October 2005
- Subjects
DRUG resistance in cancer cells; HEALTH outcome assessment; CANCER cells; APOPTOSIS; POSITRON emission tomography; CANCER research
- Publication
British Journal of Cancer, 2005, Vol 93, Issue 9, p973
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1038/sj.bjc.6602821